XML 17 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
 1 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2025
Nov. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure              
Pay vs Performance Disclosure, Table    
Value of Initial Fixed $100 Investment Based on:
Year
Summary Compensation Table Total for PEO1 (1)
Compensation Actually Paid to PEO1 (2)
Average Summary Compensation Table Total for Other NEOs (1)Average Compensation Actually Paid to Other NEOs (2)Cumulative Total Shareholder Return (3)Peer Group Cumulative Total Shareholder Return (4)Net Income (Millions) (5)Company-Selected Measure: Net Revenue (Millions) (6)
2025
$—$—$4,064,069$13,209$7$125$(136)$655.353
2024
$1,539,088$796,235$5,442,730$9,679,033$35$118$(169)$605.220
2023
$1,521,026$(5,225,762)$5,473,623$(1,202,184)$18$119$(207)$509.338
2022$2,278,951$2,075,757$6,477,346$5,788,737$87$114$(93)$537.840
2021$1,179,283$(31,518,263)$5,653,771$(12,875,003)$89$126$(58)$535.031

Value of Initial Fixed $100 Investment Based on:
Year
Summary Compensation Table Total for PEO2 (1)
Compensation Actually Paid to PEO2 (2)
Average Summary Compensation Table Total for Other NEOs (1)Average Compensation Actually Paid to Other NEOs (2)Cumulative Total Shareholder Return (3)Peer Group Cumulative Total Shareholder Return (4)Net Income (Millions) (5)Company-Selected Measure: Net Revenue (Millions) (6)
2025
$13,198,354$(4,503,021)$4,064,069$13,209$7$125$(136)$655.353

Value of Initial Fixed $100 Investment Based on:
Year
Summary Compensation Table Total for PEO3 (1)
Compensation Actually Paid to PEO3 (2)
Average Summary Compensation Table Total for Other NEOs (1)Average Compensation Actually Paid to Other NEOs (2)Cumulative Total Shareholder Return (3)Peer Group Cumulative Total Shareholder Return (4)Net Income (Millions) (5)Company-Selected Measure: Net Revenue (Millions) (6)
2025
$6,975,329$62,298$4,064,069$13,209$7$125$(136)$655.353
        
Company Selected Measure Name     Net Revenue        
Named Executive Officers, Footnote     Mr. Danziger was our PEO for the years 2021 through 2024 ("PEO1"). For 2025, Ms. Cordova was our PEO from January 1, 2025 through November 30, 2025 (listed as "PEO2"). Mr. Leonard was our PEO from December 1, 2025 through December 31, 2025 (listed as "PEO3"). The other named executive officers represented in the Other NEO average amounts above are:
• 2025: Mr. Brackmann, Dr. Leupin, Mr. Puri and Dr. Weinberg
• 2024: Ms. Cordova, Mr. Leonard, Dr. Weinberg and Mr. Ben-Arye
• 2023: Ms. Cordova, Mr. Groenhuysen, Mr. Leonard, Mr. Shah and Mr. Ben-Arye
• 2022: Ms. Cordova, Mr. Groenhuysen, Mr. Leonard and Mr. Shah
• 2021: Ms. Cordova, Mr. Groenhuysen, Mr. Longsworth and Mr. Shah
        
Peer Group Issuers, Footnote     The peer group represented is the NASDAQ Biotechnology Index which is the peer group represented in Part II, Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities of our Annual Report. The Cumulative TSR for the peer group reflects weighting of each constituent company’s TSR by its stock market capitalization.        
PEO Total Compensation Amount       $ 1,539,088 $ 1,521,026 $ 2,278,951 $ 1,179,283
PEO Actually Paid Compensation Amount       796,235 (5,225,762) 2,075,757 (31,518,263)
Adjustment To PEO Compensation, Footnote     The following adjustments were made to summary compensation totals to determine the Compensation Actually Paid values to our PEOs and the Average Compensation Actually Paid values to our Other NEOs. The Fair Value of Equity Award values were determined using a Black-Scholes option-pricing model. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year.
20252024202320222021
Summary Compensation Table Total for PEO1
$— $1,539,088 $1,521,026 $2,278,951 $1,179,283 
Subtract: Grant Date Fair Value of Equity Awards$— $— $— $(579,437)$— 
Add: Year-end Fair Value of Equity Awards Granted in the Applicable Fiscal Year that are Outstanding and Unvested$— $— $— $498,330 $— 
Add (Subtract): Change as of the Vesting Date (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that Vested in the Covered Fiscal Year.
$— $4,707 $(6,801,975)$(186,784)$(31,193,820)
Add (Subtract): Change as of the end of the Fiscal Year (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that are Outstanding and Unvested as of the end of the Covered Fiscal Year
$— $(747,560)$55,187 $64,697 $(1,503,726)
Add: Value of Dividends on Stock Awards not Otherwise Reflected in Fair Value or Total Compensation$— $— $— $— $— 
Compensation Actually Paid to PEO1
$— $796,235 $(5,225,762)$2,075,757 $(31,518,263)

2025
Summary Compensation Table Total for PEO2
$13,198,354 
Subtract: Grant Date Fair Value of Equity Awards$(11,002,779)
Add: Year-end Fair Value of Equity Awards Granted in the Applicable Fiscal Year that are Outstanding and Unvested$1,120,742 
Add (Subtract): Change as of the Vesting Date (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that Vested in the Covered Fiscal Year.
$(1,056,998)
Add (Subtract): Change as of the end of the Fiscal Year (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that are Outstanding and Unvested as of the end of the Covered Fiscal Year
$(1,837,478)
Subtract: Fair Value (as of the Prior Fiscal Year End) of Equity Awards Granted in Prior Fiscal Years that Failed to Meet Vesting Conditions in the Covered Fiscal Year
$(4,924,862)
Add: Value of Dividends on Stock Awards not Otherwise Reflected in Fair Value or Total Compensation$— 
Compensation Actually Paid to PEO2
$(4,503,021)
2025
Summary Compensation Table Total for PEO3
$6,975,329 
Subtract: Grant Date Fair Value of Equity Awards$(6,001,013)
Add: Year-end Fair Value of Equity Awards Granted in the Applicable Fiscal Year that are Outstanding and Unvested$4,352,940 
Add (Subtract): Change as of the Vesting Date (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that Vested in the Covered Fiscal Year.
$(1,017,541)
Add (Subtract): Change as of the end of the Fiscal Year (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that are Outstanding and Unvested as of the end of the Covered Fiscal Year
$(4,247,417)
Add: Value of Dividends on Stock Awards not Otherwise Reflected in Fair Value or Total Compensation$— 
Compensation Actually Paid to PEO3
$62,298 
        
Non-PEO NEO Average Total Compensation Amount     $ 4,064,069 5,442,730 5,473,623 6,477,346 5,653,771
Non-PEO NEO Average Compensation Actually Paid Amount     $ 13,209 9,679,033 (1,202,184) 5,788,737 (12,875,003)
Adjustment to Non-PEO NEO Compensation Footnote    
20252024202320222021
Average Summary Compensation Table Total for Other NEOs$4,064,069 $5,442,730 $5,473,623 $6,477,346 $5,653,771 
Subtract: Grant Date Fair Value of Equity Awards$(3,001,011)$(4,503,726)$(4,661,927)$(5,608,911)$(5,122,931)
Add: Year-end Fair Value of Equity Awards Granted in the Applicable Fiscal Year that are Outstanding and Unvested$2,032,962 $7,546,385 $637,101 $5,003,251 $1,559,370 
Add (Subtract): Change as of the Vesting Date (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that Vested in the Covered Fiscal Year.
$(660,862)$40,845 $(3,671,596)$(121,327)$(13,778,889)
Add (Subtract): Change as of the end of the Fiscal Year (from the end of the Prior Fiscal Year) in Fair Value of any Awards Granted in any Prior Fiscal Year that are Outstanding and Unvested as of the end of the Covered Fiscal Year
$(2,421,950)$1,152,799 $1,020,615 $38,378 $(1,186,323)
Add: Value of Dividends on Stock Awards not Otherwise Reflected in Fair Value or Total Compensation$— $— $— $— $— 
Average Compensation Actually Paid to Other NEOs$13,209 $9,679,033 $(1,202,184)$5,788,737 $(12,875,003)
        
Compensation Actually Paid vs. Total Shareholder Return    
The following chart sets forth the relationship between Compensation Actually Paid ("CAP") to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Cumulative TSR over the five most recently completed fiscal years.
The chart below illustrates the mostly positive correlation between Compensation Actually Paid and the TSR of our Ordinary Shares and of the Nasdaq Biotechnology index over the same period. The TSR amounts in the graph assume the investment of $100 on December 31, 2020 and the reinvestment of any dividends paid. This correlation is to be expected due to the significant value equity awards have as a percentage of our NEOs’ total overall compensation packages. This relationship can be seen for both our PEO and our other NEOs as a group most notably in 2021. Our PEO did not receive significant equity awards from 2020 through 2024 (see "Long-Term Incentives - 2020 Performance Awards to Executive Chairman" on page 57).
CAP vs TSR.gif
        
Compensation Actually Paid vs. Net Income    
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the five most recently completed fiscal years.
CAP vs Net Income.gif
        
Compensation Actually Paid vs. Company Selected Measure    
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Revenue.
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Revenue during the five most recently completed fiscal years.
CAP vs Net Revenue.gif
        
Total Shareholder Return Vs Peer Group    
The following chart sets forth the relationship between Compensation Actually Paid ("CAP") to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Cumulative TSR over the five most recently completed fiscal years.
The chart below illustrates the mostly positive correlation between Compensation Actually Paid and the TSR of our Ordinary Shares and of the Nasdaq Biotechnology index over the same period. The TSR amounts in the graph assume the investment of $100 on December 31, 2020 and the reinvestment of any dividends paid. This correlation is to be expected due to the significant value equity awards have as a percentage of our NEOs’ total overall compensation packages. This relationship can be seen for both our PEO and our other NEOs as a group most notably in 2021. Our PEO did not receive significant equity awards from 2020 through 2024 (see "Long-Term Incentives - 2020 Performance Awards to Executive Chairman" on page 57).
CAP vs TSR.gif
        
Tabular List, Table    
Net Revenue
TSR
Adjusted EBITDA
Active Patients
Clinical Trial Milestones
        
Total Shareholder Return Amount     $ 7 35 18 87 89
Peer Group Total Shareholder Return Amount     125 118 119 114 126
Net Income (Loss)     $ (136,000,000) $ (169,000,000) $ (207,000,000) $ (93,000,000) $ (58,000,000)
Company Selected Measure Amount     655,353,000 605,220,000 509,338,000 537,840,000 535,031,000.000
PEO Name Mr. Leonard Ms. Cordova   Mr. Danziger Mr. Danziger Mr. Danziger Mr. Danziger
Additional 402(v) Disclosure     Cumulative Total Shareholder Return (“TSR”) represents the price appreciation of our Ordinary Shares plus dividends paid (assuming reinvestment) during the measurement period beginning as of market close December 31, 2020 through December 31 of the year noted.Net Income amounts reported here are the net income amounts reflected in the our audited consolidated financial statements for the applicable years.Net Revenue amounts reported here are the net revenue amounts reflected in the our audited consolidated financial statements for the applicable years.        
Measure:: 1              
Pay vs Performance Disclosure              
Name     Net Revenue        
Measure:: 2              
Pay vs Performance Disclosure              
Name     TSR        
Measure:: 3              
Pay vs Performance Disclosure              
Name     Adjusted EBITDA        
Measure:: 4              
Pay vs Performance Disclosure              
Name     Active Patients        
Measure:: 5              
Pay vs Performance Disclosure              
Name     Clinical Trial Milestones        
Mr. Danziger [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     $ 0        
PEO Actually Paid Compensation Amount     0        
Ms. Cordova [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     13,198,354        
PEO Actually Paid Compensation Amount     (4,503,021)        
Mr. Leornard [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     6,975,329        
PEO Actually Paid Compensation Amount     62,298        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       $ 0 $ 0 $ (579,437) $ 0
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       0 0 498,330 0
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       (747,560) 55,187 64,697 (1,503,726)
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       4,707 (6,801,975) (186,784) (31,193,820)
PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount       0 0 0 0
PEO | Mr. Danziger [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Mr. Danziger [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Mr. Danziger [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Mr. Danziger [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Mr. Danziger [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Ms. Cordova [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (11,002,779)        
PEO | Ms. Cordova [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     1,120,742        
PEO | Ms. Cordova [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (1,837,478)        
PEO | Ms. Cordova [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (1,056,998)        
PEO | Ms. Cordova [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (4,924,862)        
PEO | Ms. Cordova [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Mr. Leornard [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (6,001,013)        
PEO | Mr. Leornard [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     4,352,940        
PEO | Mr. Leornard [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (4,247,417)        
PEO | Mr. Leornard [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (1,017,541)        
PEO | Mr. Leornard [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (3,001,011) (4,503,726) (4,661,927) (5,608,911) (5,122,931)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     2,032,962 7,546,385 637,101 5,003,251 1,559,370
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (2,421,950) 1,152,799 1,020,615 38,378 (1,186,323)
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (660,862) 40,845 (3,671,596) (121,327) (13,778,889)
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     $ 0 $ 0 $ 0 $ 0 $ 0